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Abstract
Conventional cardiopulmonary bypass surgery (CCPB) increases the iron loading of plasma transferrin often to a state of
plasma iron overload, with the presence of low molecular mass iron. Such iron is a potential risk factor for oxidative stress
and microbial virulence. Here we assess ‘off-pump’ coronary artery surgery on the beating heart for changes in plasma iron
chemistry. Seventeen patients undergoing cardiac surgery using the ‘Octopus’ myocardial wall stabilisation device were
monitored at five time points for changes in plasma iron chemistry. This group was further divided into those (n = 9) who had
one- or two- (n = 8) vessel grafts, and compared with eight patients undergoing conventional coronary artery surgery.
Patients undergoing beating heart surgery had significantly lower levels of total plasma non-haem iron, and a decreased
percentage saturation of their transferrin at all time points compared to conventional bypass patients. Plasma iron overload
occurred in only one patient undergoing CCPB. Beating heart surgery appears to decrease red blood cell haemolysis, and
tissue damage during the operative procedures and thereby significantly decreases the risk of plasma iron overload associated
with conventional bypass. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
The use of cardiopulmonary bypass to facilitate
cardiac surgery exposes the circulating blood to
non-physiological surfaces and mechanical shear
stresses. Such treatment is known to activate several
regulatory cascades (reviewed in [1]). As a result, red
blood cells become lysed and release their cell con-
tents such as haemoglobin and catalase, and neutro-
phils become activated to produce superoxide (O32 )
and hydrogen peroxide (H2O2) [2]. Hydrogen perox-
ide can react with haemoglobin to release redox ac-
tive, low molecular mass iron (LMrFe) from the
haem moiety [3]. This redox active iron is able to
participate in organic and inorganic oxygen radical
reactions, such as stimulating lipid peroxidation and
catalysing the formation of the highly damaging hy-
droxyl radical (cOH). Iron is also a virulence factor
for microbial growth [4].
The ability of iron to redox cycle and transfer
electrons to molecular oxygen to form a variety of
reactive oxygen species (ROS) has necessitated the
evolution of ligands that decrease or prevent un-
wanted electron transfers. Thus, iron transporting
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proteins such as transferrin and lactoferrin, and iron
storage proteins such as ferritin and haemosiderin,
sequester iron in forms that minimise the transfer
of electrons from iron to molecular oxygen. [5,6].
Normal human plasma, therefore contains no detect-
able LMrFe, because the iron-binding protein trans-
ferrin is usually less than 30% loaded with iron and
retains a considerable iron-binding capacity. When,
however, the cellular release of LMrFe exceeds the
iron-binding capacity of transferrin, forms of iron
not bound to transferrin exist in the plasma (non-
transferrin bound iron). Plasma iron not bound to
the high a⁄nity iron-binding sites of transferrin is
often associated with ligands such as citrate, phos-
phate and acetate. It may, however, also be loosely
associated with other proteins such as albumin. In
both cases iron ions can readily be removed by che-
lators with a stronger a⁄nity for iron. Bleomycin,
which is a weak iron chelator (it cannot remove
iron from the high a⁄nity binding sites of transfer-
rin), can be used to detect and measure such forms of
iron [7] in plasma.
In certain patients undergoing cardiopulmonary
bypass the release of iron is so great that it can
saturate the plasma transferrin and lead to transient
plasma iron overload [8^10]. In most patients, how-
ever, iron release is minimal and leads to an increase
in the iron loading of transferrin to around 50%
saturation [8,9].
Recently, there has been renewed interest in per-
forming coronary artery surgery on the beating heart
[11], prompted partly by the detrimental e¡ects of
cardiopulmonary bypass [12,13], and partly by the
availability of new instrumentation that makes it
possible [14]. One such technique of beating heart
coronary artery surgery (BHS) utilises the ‘Octopus’
myocardial stabilisation device [15^17]. This tech-
nique allows easy access to anterior wall vessels on
the heart, and relatively straightforward access to the
posterior wall. A major advantage of this procedure
is that it does not involve extracorporeal pumping
and circulation of blood, which are primary contrib-
utors to red blood cell lysis. We have previously ar-
gued [9] that the increased release of iron seen during
conventional cardiopulmonary bypass (CCPB) origi-
nates from signi¢cant red blood cell lysis. In order to
address this question directly we have compared pa-
tients who have undergone o¡-pump cardiac surgery
using the beating heart method to patients who
underwent surgery requiring conventional cardiopul-
monary bypass procedures.
2. Methods and materials
Bleomycin sulphate and calf thymus DNA were
obtained from the Sigma Chemical Co., Poole, Dor-
set, UK. Radial immunodi¡usion plates for the
transferrin assays were obtained from Dade Behring
Diagnostics, Milton Keynes, UK. All other chemi-
cals were of the highest grade available from Fisher
Scienti¢c UK, Loughborough, Leics, UK.
2.1. Patient details
We studied 17 patients (age range 43^73 years:
four female and 13 male) who underwent cardiac
surgery using the ‘Octopus’ myocardial wall stabili-
sation device (Medtronic, Grand Rapids, MI, USA).
This group of patients were further divided into
those who had one (nine patients) or two (eight pa-
tients) vessel grafts during the operative procedure.
Eight patients (age range 56^70 years) who under-
went conventional coronary artery surgery with car-
diopulmonary bypass for two-vessel grafts were also
studied. The patient characteristics are shown in Ta-
ble 1. Institutional Ethical Committee approval was
obtained for this study, and informed consent ob-
tained from all patients.
2.2. Coronary artery surgery without
cardiopulmonary bypass
The operation was performed through a median
sternotomy. After harvesting the bypass conduits,
heparin was given at a dose of 1.5 mg/kg. A coronary
sinus catheter was inserted to allow sampling of cor-
onary venous blood. The ‘Octopus’ myocardial sta-
bilisation device (Medtronic) consists of two paddles
with suction cups on the underside [15^17]. These
were placed on the epicardial surface on either side
of the coronary artery to be grafted. 2/0 prolene su-
tures were then positioned proximal and distal to the
site of anastomosis and gently tightened to occlude
coronary £ow and therefore allow grafting of the
coronary artery in a bloodless ¢eld. When the anas-
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tomosis was complete, the coronary snares were re-
leased to restore coronary blood £ow. The proximal
anastomosis was performed using a side biting clamp
on the aorta when reversed saphenous vein was used
as a conduit for grafting the right coronary artery.
All left anterior descending arteries were grafted with
a predicted left internal mammary artery.
2.3. Coronary artery surgery with cardiopulmonary
bypass
Median sternotomy was performed. After harvest-
ing the bypass graft conduits the patients were pre-
pared for cardiopulmonary bypass. Heparin sulphate
was given at a dose of 3 mg/kg. Cardiopulmonary
bypass was established with ascending aortic and
single right atrial cannulation. The extracorporeal
circuit utilised a membrane oxygenator primed with
1800 ml of crystalloid solution and 500 ml of albu-
min. The systemic perfusion £ow rate used was be-
tween 1.6 l/min per m2 at 32‡C to 2.2 l/min per m2 at
37‡C. We used systemic hypothermia (32‡C naso-
pharyngeal temperature), and haemodilution (hae-
matocrit value 20^25%).
A DLP triple lumen catheter (Medtronic) was
positioned in the coronary sinus and its proximal
pressure monitored and maintained at 30^40
mmHg during retrograde perfusion. Cold blood car-
dioplegia was used for myocardial protection, the
¢rst two-thirds of the cardioplegia given antegradely
and subsequently maintained by potassium enriched
autologous blood given retrogradely via the coronary
sinus every 15 min.
After the distal anastomoses were complete the
aortic cross-clamp was removed and the proximal
anastomoses fashioned with a side biting clamp on
the aorta during myocardial perfusion. Immediately
prior to release of the aortic cross-clamp, a 5-min
period of warm reperfusion (600 ml of potassium
enriched blood at 37‡C via the coronary sinus cath-
eter) was administered, while the patient’s core tem-
perature was 35^37‡C.
2.4. Blood sample collection
During beating heart coronary artery surgery,
blood samples were obtained from the coronary si-
nus and radial artery at the following times: before
coronary occlusion (pre-ischaemia), and 1, 4, 10 and
20 min after release of the coronary snare (post-is-
chaemia). In the case of coronary artery surgery with
conventional cardiopulmonary bypass, blood sam-
ples were obtained at the same times after cross-
clamp release.
Blood samples were collected into lithium heparin
tubes, stored at 4‡C, and transported to the labora-
tory at the end of the operation for immediate sep-
aration and analysis.
2.5. Total plasma non-haem iron and iron-binding
capacity
The total plasma non-haem iron and the iron-
binding capacity were measured using a Sigma kit
assay based on the ferrozine spectrophotometric
method.
Where appropriate, values were corrected to the
total plasma protein value (assayed by the Lowry
method) to adjust for the haemodilution inherent in
bypass procedures.
2.6. Total plasma haemoglobin
Plasma haemoglobin concentration in mg/100 ml
was measured spectrophotometrically by determining
(A413U13.5)-(A453U8.4).
2.7. Transferrin
Plasma transferrin was quantitated using radial
immunodi¡usion plates containing a polyclonal anti-
body to human transferrin and pure standards of
human apotransferrin. The percentage saturation of
transferrin with iron was derived from the measured
iron-binding capacity. This was found to be in close
agreement with values calculated from the amount of
transferrin present.
2.8. Bleomycin assay for LMrFe
Low molecular mass iron, or redox active iron,
was measured using the bleomycin assay [18]. Brie£y
the reaction mixture contained DNA (1 mg/ml),
bleomycin (1.5 units/ml), magnesium chloride (50
mM) and the plasma sample bu¡ered to pH 7.4
with a Tris salt. In the presence of added ascorbate
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(7.5 mM), iron that is able to be chelated from the
plasma sample by bleomycin can degrade DNA in
vitro with the release of malondialdehyde from its
deoxyribose moiety, and the released malondialde-
hyde can be measured spectrophotometrically by re-
action with 2-thiobarbituric acid.
2.9. Data analysis
All results are shown as mean þ S.E.M. Statistical
comparisons were made by non-parametric one-way
analysis of variance (ANOVA), with post hoc tests
performed by Dunn’s multiple comparisons test.
P6 0.05 was considered to be signi¢cant.
3. Results
There were no statistical di¡erences pre-ischaemia
for any parameters between the three groups studied.
After reperfusion, however, total plasma non-haem
iron levels were signi¢cantly elevated (P6 0.05) in
the conventional cardiopulmonary by-pass group
(CCPB) compared to the beating heart surgery pa-
tients (BHS) (see Fig. 1). Previous studies [9] have
shown that pre-bypass levels of plasma non-haem
iron in a similar age group (mean age 60.5 years)
receiving cold blood cardioplegia are 0.303 þ 0.12
nmol/mg protein (n = 17). This compares to a value
of 0.220 þ 0.02 found in normal healthy control sub-
jects (n = 12) [8,9]. Elevation of iron occurred at each
time point studied. Post-ischaemia, plasma transfer-
rin levels were lower in the CCPB patients than in
the BHS group receiving one bypass graft (Table 2).
Values for transferrin, however, only reached signi¢-
cance at 20 min post-ischaemia (Table 2). Plasma
Fig. 1. Comparison of the total non-haem iron levels (nmol/mg
protein) in the three surgical groups studied. *P6 0.05,
**P6 0.01 when compared to CCPB. Data are shown as
mean þ S.E.M. White bars, BHS one-vessel graft; black bars,
BHS two-vessel graft; shaded bars, conventional bypass sur-
gery.
Table 1
Patient characteristics
Variable BHS CCPB
One-vessel grafting (n = 9) Two-vessel grafting (n = 8) Two-vessel grafting (n = 8)
Age (median(range)) (years) 65 (55^73) 58 (43^69) 62 (56^70)
Sex (M/F) 6/3 7/1 5/3
Ischaemic time (mean (S.D.)) (min) 17 (4) 32 (8)2 44 (7)*
Vessels grafted (%)
LAD 7 (78) 8 (100) 8 (100)
RCA 2 (22) 8 (100) 5 (63)
CX 0 (0) 0 (0) 3 (38)
LVEF (mean (SD)) % 60 (7) 62 (5) 62 (8)
Previous MI
Anterior (%) 1 (1) 1 (1) 1 (1)
Inferior (%) 1 (1) 0 (0) 1 (1)
Medication (%)
Beta blockers 8 (80) 5 (63) 4 (50)
Calcium antagonists 7 (70) 4 (50) 7 (88)
Nitrates 4 (40) 5 (63) 4 (50)
Patient characteristics for the three surgical groups studied are shown. CCPB, conventional cardiopulmonary bypass; LAD, left anteri-
or descending artery; RCA, right coronary artery; CX, circum£ex artery; LVEF, left ventricular ejection fraction; MI, myocardial in-
farction. *P6 0.01 vs. non-CPB one- and two-vessel grafting. 2P6 0.001 vs. non-CPB one-vessel grafting.
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iron-binding capacity, a measure of available iron-
binding sites on plasma transferrin, did not show
any signi¢cant di¡erences between the three patient
groups studied (Table 3). The degree to which plas-
ma transferrin was already loaded with iron, mea-
sured as the percentage iron saturation of transferrin,
however, showed signi¢cant di¡erences within the
patient groups (Fig. 2). An increased iron-saturation
of plasma transferrin was seen in the CCPB group at
all time points post-ischaemia compared to both
BHS patient groups (Fig. 2). Although pre-bypass
samples were not available to us for this study, we
have previously shown [9] that patients of a similar
age (mean 60.5 years) requiring bypass surgery
present at pre-bypass with a 40 þ 4% iron saturation
of plasma transferrin (n = 17). Normal healthy sub-
jects, however, show a 28 þ 2% iron saturation of
plasma transferrin (n = 12) [8]. One patient in the
CCPB group was in plasma iron overload with plas-
ma transferrin showing a 100% saturation with iron.
As previously reported [8,9], this represents around
13% of CCPB who go into plasma iron overload and
show the presence of low molecular mass iron in
their plasma. Plasma iron overload was not seen in
any of the BHS patients, consistent with their lower
percentage iron saturation of transferrin.
Plasma haemoglobin levels were measured in rep-
resentative one-vessel and two-vessel BHS patients,
and in CCPB patients during the operative proce-
dures. Pre-ischaemia values for haemoglobin were
similar in all groups, but increased substantially at
all time points in the CCPB group compared to the
BHS patients (Fig. 3).
Table 3
Total iron-binding capacity (nmol/mg protein)
Time point Beating heart surgery (BHS) Conventional bypass surgery
(CCPB)
ANOVA P value
One-vessel grafting
(n = 9)
Two-vessel grafting
(n = 8)
Two-vessel grafting via CPB
(n = 8)
Pre-ischaemia 1.049 þ 0.106 0.922 þ 0.054 1.097 þ 0.098 0.462
1 min reperfusion 1.03 þ 0.088 0.904 þ 0.052 1.019 þ 0.081 0.440
4 min reperfusion 1.023 þ 0.080 0.970 þ 0.064 1.005 þ 0.084 0.907
10 min reperfusion 1.013 þ 0.082 0.949 þ 0.049 1.033 þ 0.064 0.481
20 min reperfusion 1.018 þ 0.076 0.863 þ 0.073 1.005 þ 0.084 0.567
Iron-binding capacity (nmol/mg protein) of the plasma samples from the surgical groups studied are shown. Data are shown as
mean þ S.E.M. Pre-bypass samples were not provided for these patients. Previous studies [21] have shown that in a similar age group
of patients (52.3 years) receiving cold blood cardioplegia, the pre-bypass plasma total iron-binding value was 0.690 þ 0.047 nmol/mg
protein (n = 10). This compares to a plasma total iron-binding value of 0.916 þ 0.044 nmol/mg protein found in normal healthy con-
trols (n = 10).
Table 2
Transferrin (nmol/mg protein)
Time point Beating heart surgery (BHS) Conventional bypass surgery
(CCPB)
ANOVA P value
One-vessel grafting
(n = 9)
Two-vessel grafting
(n = 8)
Two-vessel grafting via CPB
(n = 8)
Pre-ischaemia 0.491 þ 0.030 0.438 þ 0.019 0.518 þ 0.059 0.368
1 min reperfusion 0.488 þ 0.036 0.413 þ 0.012 0.481 þ 0.040 0.220
4 min reperfusion 0.484 þ 0.035 0.421 þ 0.014 0.476 þ 0.045 0.384
10 min reperfusion 0.477 þ 0.035 0.455 þ 0.014 0.490 þ 0.036 0.286
20 min reperfusion 0.486 þ 0.035 0.407 þ 0.026 0.475 þ 0.026 0.156
Plasma transferrin levels (nmol/mg protein) in the surgical groups studied are shown. Data are shown as mean þ S.E.M. Pre-bypass
samples were not provided for these patients. Previous studies [8] have shown that in a similar age group of patients (60.5 years) re-
ceiving cold blood cardioplegia, the pre-bypass plasma transferrin value was 0.365 þ 0.022 nmol/mg protein (n = 17). This compares to
a plasma transferrin value of 0.461 þ 0.022 nmol/mg protein found in normal healthy controls (n = 12).
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4. Discussion
Extracorporeal circulation exposes blood to non-
physiological surfaces and mechanical stress. Circu-
lation and oxygenation can result in the activation of
neutrophils and several enzyme cascades, and the
lysis of red blood cells unleashing clotting, ¢brino-
lytic and complement. A combination of these events
can cause the release of proteolytic enzymes and the
formation of reactive forms of oxygen such as super-
oxide (O32 ) and hydrogen peroxide (H2O2). Some or
all of these changes may contribute to the recognised
adverse e¡ects of bypass surgery such as those occur-
ring during the systemic intravascular in£ammatory
response.
Hydrogen peroxide can react with haemoglobin to
release redox active forms of iron from the haem
moiety [3]. Redox active iron that is not tightly se-
questered in biological systems has the potential to
be cytotoxic by generating reactive and damaging
intermediates such as the hydroxyl radical (cOH) (re-
viewed in [19].
The iron-binding capacity of transferrin provides a
potent antioxidant potential against iron-driven free
radical reactions, and part of this protection is lost in
most cardiopulmonary bypass patients undergoing
conventional surgery [8]. When the plasma transfer-
rin becomes fully saturated with iron, all iron-bind-
ing antioxidant activity is lost and plasma shows pro-
oxidant properties [8], because non-transferrin bound
iron is available in a reactive form to catalyse radical
formation. A fully iron saturated transferrin, with
the presence of non-transferrin bound iron was
seen in one of the conventional CPB patients studied
here (V13%), a ¢nding in agreement with previously
published data [8,9].
In patients undergoing coronary artery surgery
without cardiopulmonary bypass, we did not see
such a marked increase in the iron saturation of
transferrin, and unlike the conventional cardiopul-
monary bypass group no patients within this group
went into plasma iron overload. This signi¢cant dif-
ference in iron saturation of plasma transferrin may
be due to the shorter duration of ischaemia, and to
the regional rather than global ischaemia induced
during BHS compared to CCPB surgery. In fact,
we have shown that the release of cardiac troponin
T, a highly speci¢c marker of myocardial injury, is
signi¢cantly lower during beating heart surgery,
suggesting a lesser degree of myocardial damage
compared to conventional coronary artery surgery
[20].
We suggest that the increase in total non-haem
iron seen during CCPB is most likely a feature of
increased haemolysis due to the shear stresses placed
upon red blood cells inherent in CCPB, although
damage to heart tissue may also contribute. There
is considerably less haemolysis, and less tissue dam-
age observed during beating heart surgery, and these
may be the reasons for the lower total plasma iron
levels, as well as for the decreased iron loading of
transferrin, (below 50% saturation) compared to the
CCPB group (s 50% saturation). We conclude that
beating heart surgery signi¢cantly decreases the risk
of iron toxicity leading to the potential for increased
oxidative damage and microbial virulence.
Fig. 3. Plasma haemoglobin levels (mg/100 ml plasma) in the
surgical groups. Data are shown as mean þ S.E.M. White bars,
BHS one-vessel graft ; black bars, BHS two-vessel graft ; shaded
bars, conventional bypass surgery.
Fig. 2. Comparison of the percentage iron saturation of trans-
ferrin in the surgical groups. *P6 0.05, **P6 0.01 when com-
pared to CCPB. Data are shown as mean þ S.E.M. White bars,
BHS one-vessel graft ; black bars, BHS two-vessel graft ; shaded
bars, conventional bypass surgery.
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